# To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

> **NCT01009242** · PHASE1,PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 40 (actual)

## Conditions studied

- Arthritis
- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** CDP6038
- **BIOLOGICAL:** CDP6038
- **BIOLOGICAL:** CDP6038
- **OTHER:** Placebo IV
- **OTHER:** Placebo SC
- **DRUG:** CDP 6038 SC
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT01009242
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009242, "To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01009242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*